Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$60.12 USD

60.12
138,732

+0.46 (0.77%)

Updated Oct 17, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

RARE's Wilson Disease Candidate Betters Standard Therapy in Study

by Zacks Equity Research

Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study.

Zevra Stock Surges Close to 70% in 3 Months: Here's Why

by Zacks Equity Research

The FDA approval for ZVRA's Miplyffa (arimoclomol) capsules in September for treating Niemann-Pick disease type C drives the stock.

GILD Grants Right for HIV PrEP Candidate to Six Generic Companies

by Zacks Equity Research

Gilead signs non-exclusive, royalty-free voluntary licensing agreements with six generic companies to market its investigational medicine, lenacapavir, for HIV Prevention.

AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use

by Zacks Equity Research

The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in first-quarter 2025.

STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls

by Zacks Equity Research

Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications and plans to reduce the workforce by 40%.

IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag

by Zacks Equity Research

The FDA bestows a Fast Track designation to Ionis' investigational candidate, zilganersen, for treating a rare neurological disorder called Alexander disease.

Here's Why Investors Should Consider Buying Corcept Stock Now

by Zacks Equity Research

Here, we are discussing some reasons why investing in CORT stock now may turn out to be a prudent move.

AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use

by Zacks Equity Research

The FDA grants priority review to AZN's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer. A decision is due in first-quarter 2025.

MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine

by Zacks Equity Research

Moderna doses the first participant in a phase III study evaluating its mRNA norovirus vaccine candidate, mRNA-1403, in the United States.

AbbVie Seeks Approval for Lung Cancer Candidate Teliso-V

by Zacks Equity Research

ABBV submits a BLA for Teliso-V to the FDA for treating previously treated non-small cell lung cancer patients with c-Met overexpression.

SAVA Stock Down on Settling Misleading Alzheimer's Study Data Claims

by Zacks Equity Research

Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges brought against it by the SEC.

Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies

by Zacks Equity Research

Biomea stock rises 9% after the FDA lifts clinical hold on two phase I/II studies evaluating the company's lead candidate, BMF-219, for diabetes.

MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study

by Zacks Equity Research

The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.

AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC

by Zacks Equity Research

The FDA approves AstraZeneca's Tagrisso for treating unresectable, stage III EGFR-mutated non-small cell lung cancer.

CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study

by Zacks Equity Research

Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data.

Roche's Lupus Study for Gazyva Meets Primary & Key Secondary Goals

by Zacks Equity Research

RHHBY announces meeting primary and key secondary goals in the late-stage study of its lymphoma drug, Gazyva/Gazyvaro, for treating active lupus nephritis.

Biogen's Lupus Candidate Meets Key Goals in Phase III Study

by Zacks Equity Research

The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets the primary endpoint.

WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study

by Zacks Equity Research

Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.

BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal

by Zacks Equity Research

The pivotal BHV4157-206-RWE study evaluating Biohaven's pipeline candidate, troriluzole, for treating spinocerebellar ataxia meets its primary endpoint.

MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers

by Zacks Equity Research

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.

Are Medical Stocks Lagging Argenx (ARGX) This Year?

by Zacks Equity Research

Here is how argenex SE (ARGX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 9.68% and 8.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?